US hospital STI testing sales drop amid “multifactorial” causes
GlobalData analysis reveals that in H1 2025, US hospital sales volume for chlamydia/gonorrhoea tests decreased by 1.7% versus H1 2024, and by 27.8% for tests targeting bacterial vaginosis.